Inhibition of Neovascularization and Tumor Growth, and Facilitation of Wound Repair, by Halofuginone, an Inhibitor of Collagen Type I Synthesis

Neoplasia

Volumn 1, Issue 4, 1999, Pages 321-329

  Abramovitch, Rinat ^a   Dafni, Hagit ^a   Neeman, Michal ^a   Nagler, Arnon ^b   Pines, Mark ^c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c VOLCANI CENTER   (Israel)

Author keywords

C6 glioma; Collagen type I; Halofuginone; MRI

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGEN; HALOFUGINONE; PIPERIDINE DERIVATIVE; PROTEIN SYNTHESIS INHIBITOR; QUINAZOLINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ANIMAL; ARTICLE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; IN SITU HYBRIDIZATION; KINETICS; MALE; METABOLISM; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PATHOLOGY; TIME; VASCULARIZATION; WOUND HEALING;

ANIMALS; ANTINEOPLASTIC AGENTS; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; IN SITU HYBRIDIZATION; KINETICS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PIPERIDINES; PROTEIN SYNTHESIS INHIBITORS; QUINAZOLINES; QUINAZOLINONES; TIME FACTORS; TUMOR CELLS, CULTURED; WOUND HEALING;

EID: 0033205228     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900043     Document Type: Article

References (34)

1. Montesano R, Orci L, and Vassalli P (1983). In-vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97, 1648-1652.
2. Nicosia RF, and Madri JA (1987). The microvascular extracellular matrix. Developmental changes during angiogenesis in the aortic ring-plasma clot model. Am J Pathol 128, 78-90.
3. Madri JA, and Williams SK (1983). Capillary endothelial cell cultures: phenotypic modulation by matrix components. J Cell Biol 97, 153-165.
4. Jackson CJ, and Jenkins KL (1991). Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium. Exp Cell Res 192, 319-323.
5. Gamble JR, Matthias LJ, Meyer G, Kaur P, Russ G, Faull R, Berndt MC, and Vadas MA (1993). Regulation of in-vitro capillary tube formation by anti-integrin antibodies. J Cell Biol 121, 931-943.
6. Granot I, Bartov I, Plavnik I, Wax E, Hurwitz S, and Pines M (1991). Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Poult Sci 70, 1559-1563.
7. Levi-Schaffer F, Nagler A, Slavin S, Knopov V, and Pines M (1996). Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. J Invest Dermatol 106, 84-88.
8. Nagler A, Firman N, Feferman R, Cotev S, Pines M, and Shoshan S (1996). Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med 154, 1082-1086.
9. Pines M, Knopov V, Genina O, Lavelin I, and Nagler A (1997). Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J Hepatol 26, 391-398.
10. Nyska M, Nyska A, Rivlin E, Porat S, Pines M, Shoshan S, and Nagler A (1996). Topically applied halofuginone, an inhibitor of collagen type I transcription, reduced peritendinous fibrous adhesions following surgery. Conn Tisue Res 34, 97-103.
11. Nagler A, Rivkind AI, Raphael J, Levi-Schaffer F, Genina O, Lavelin I, and Pines M (1997). Halofuginone - an inhibitor of collagen type I synthesis - prevents post-operation abdominal adhesions formation. Ann Surg 227, 575-582.
12. Nagler A, Genina O, Lavelin I, Ohana M, and Pines M (1999). Halofuginone - an inhibitor of collagen type I synthesis - prevents formation of post-operative adhesions formation in the rat uterine horn model. Am J Obstet Gynecol 180, 558-563.
13. Elkin M, Ariel I, Miao HQ, Nagler A, Pines M, de-Groot N, Hochberg A, and Vlodavsky I (1999). Inhibition of bladder carcinoma angiogenesis, stromal support and tumor growth by halofuginone. Cancer Res 59, 4111-4118.
14. Pines M, and Nagler A (1997). Halofuginone - a novel anti-fibrotic therapy. Gen Pharmacol 30, 445-450.
15. Granot I, Hurwitz S, Halevy O, and Pines M (1993). Halofuginone: an inhibitor of collagen type I synthesis. Biochim Biophys Acta 1156, 107-112.
16. Halevy O, Nagler A, Levi-Schaffer F, Genina O, and Pines M (1996). Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem Pharmacol 52, 1057-1063.
17. Choi ET, Callow AD, Sehgal NL, Brown DM, and Ryan US (1995). Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intima hyperplasia. Arch Surg 130, 257-261.
18. Nagler A, and Pines M (1999). Topical treatment of cutaneous chronic graft versus host disease (cGvHD) with halofuginone: a novel inhibitor of collagen type I synthesis. Transplantation, in press.
19. Abramovitch R, Marikovsky M, Meir G, and Neeman M (1998). Stimulation of tumor angiogenesis by proximal wounds: spatial and temporal analysis by MRI. Br J Cancer 77, 440-447.
20. Abramovitch R, Meir G, and Neeman M (1995). Neovascularization induced growth of implanted C6 glioma multicellular spheroids: magnetic resonance microimaging. Cancer Res 55, 1956-1962.
21. Abramovitch R, Frenkiel D, and Neeman M (1998). Analysis of subcutaneous angiogenesis by gradient echo magnetic resonance imaging. Magn Reson Med 39, 813-824.
22. Schiffenbauer YS, Abramovitch R, Meir G, Nevo N, Holzinger M, Itin A, Keshet E, and Neeman M (1997). Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc Natl Acad Sci USA 94, 13203-13208.
23. Gascon-Barre M, Huet PM, Belgiorno J, Plourde V, and Coulombe PA (1989). Estimation of collagen content of liver specimens. Variation among animals and among hepatic lobes in cirrhotic rats. J Histochem Cytochem 37, 377-381.
24. Olsen L, Sherratt JA, Maini PK, and Arnold F (1997). A mathematical model for the capillary endothelial cell-extracellular matrix interactions in wound-healing angiogenesis. IMA J Math Appl Med Biol 14, 261-281.
25. DaCosta ML, Regan MC, al Sader M, Leader M, and Bouchier-Hayes D (1998). Diphenylhydantoin sodium promotes early and marked angiogenesis and results in increased collagen deposition and tensile strength in healing wounds. Surgery 123, 287-293.
26. Reed MJ, Corsa A, Pendergrass W, Penn P, Sage EH, and Abrass IB (1998). Neovascularization in aged mice: delayed angiogenesis is coincident with decreased levels of transforming growth factor beta1 and type I collagen. Am J Pathol 152, 113-123.
27. Sweeney SM, Guy CA, Fields GB, and Antonio JDS (1998). Defining the domains of type I collagen involved in heparin-binding and endothelial tube formation. Proc Natl Acad Sci USA 95, 7275-7280.
28. Cockerill GW, Varcoe L, Meyer GT, Vadas MA, and Gamble JR (1998). Early events in angiogenesis: cloning an alpha-prolyl 4-hydroxylase-like gene. Int J Oncol 13, 595-600.
29. Abramovitch R, Marikovsky M, Meir G, and Neeman M (1999). Stimulation of tumor growth by wound derived growth factors. Br J Cancer 79, 1392-1398.
30. Stout AJ, Gresser I, and Thompson WD (1993). Inhibition of wound healing in mice by local interferon alpha/beta injection. Int J Exp Pathol 74, 79-85.
31. Folkman J (1998). Antiangiogenic gene therapy. Proc Natl Acad Sci USA 95, 9064-9066.
32. Broadley KN, Aquino AM, Woodward SC, Buckley-Sturrock A, Sato Y, Rifkin DB, and Davidson JM (1989). Monospecific antibodies implicate basic fibroblast growth factor in normal wound repair. Lab Invest 61, 571-575.
33. Daly JM, Reynolds HM, Rowlands BJ, Dudrick SJ, and Copeland EM (1980). Tumor growth in experimental animals: nutritional manipulation and chemotherapeutic response in the rat. Ann Surg 191, 316-322.
34. Klurfeld DM, Weber MM, and Kritchevsky D (1987). Inhibition of chemically induced mammary and colon tumor promotion by caloric restriction in rats fed increased dietary fat. Cancer Res 47, 2759-2762.